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Abstract
Cigarette smoking is one of the most important
causes of morbidity and mortality in the general
population, and is a well-recognized risk factor for a
variety of serious clinical conditions, including
cardiovascular diseases, pulmonary diseases and
cancers.
Smoking-related morbidity and mortality are of
particular concern in patients with HIV infection, as
the prevalence of current cigarette smoking is higher
among HIV-positive patients than among the general
population.
In a study by De et al., it has been evidenced that
smoking is a risk factor for bacterial pneumonia in
HIV-positive patients and smoking cessation reduces
this risk.
HIV-positive patients who smoke have significantly
increased mortality compared to those who have
never smoked, indicating that smoking confers
different mortality risk in HIV-positive as compared to
HIV-negative patients, and lifestyle-related factors may
pose a greater hazard to long-term survival of HIV-
positive patients than those related to the HIV
infection per se.
The high prevalence of smoking among HIV
population, the many health risks that can result from
this behavior, and the proven efficacy of cessation
interventions in HIV-positive patients should
encourage HIV care providers to make smoking
cessation a high priority.
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Background
Cigarette smoking is a leading cause of morbidity and
mortality in the general population [1], and it acts as a
risk factor for many serious clinical conditions, includ-
ing coronary artery disease, myocardial infarction (MI),
stroke and pulmonary diseases. Moreover, in the general
population, smoking increases the risk for many types of
cancers, including cancers of the oral cavity, pharynx,
esophagus, stomach, pancreas, larynx, lung, cervix, urin-
ary bladder and kidney [2].
The prevalence of cigarette smoking is higher in HIV-
positive patients as compared to the general population,
with many studies reporting rates over 40% [3,4]. This
raises concern on a possible relationship between smok-
ing and the increased rate of co-morbidities and deaths
due to cardiovascular (CV) disease and cancer observed
among HIV-positive patients.
In a research article, De et al. addressed an important
issue, namely the influence of smoking on pneumonia in
HIV-positive patients, and evidenced that smoking ces-
sation can reduce the risk for bacterial pneumonia by
about 27%.
Smoking as a risk factor for AIDS- and non-AIDS
diseases
With the introduction of combination antiretroviral
therapy (ART), which resulted in a reduction of AIDS
-related diseases and deaths, serious non-AIDS diseases,
including CV diseases, pulmonary diseases and cancers
have become more common in HIV-positive patients.
The prevalence of these co-morbidities is higher among
HIV-positive patients than among individuals of the
same age in the background population [5], suggesting a
synergistic effect of underlying behavioral and pathologi-
cal conditions.
Not unexpected, smoking may even further increase
the risk for occurrence of these diseases (Table 1); for
example, in the Data Collection on Adverse Events of
Anti-HIV Drugs Study Group, the largest observational
study of CV risk on HIV-positive on ART that demon-
strated an association between the risk of MI and
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combination ART, particularly protease inhibitor ther-
apy, it has been shown that the adjusted relative rate of
MI per years of exposure to protease inhibitors was
1.16, compared to 2.83 for current smoking [6].
More recently, in the Strategies for Management of
Antiretroviral Therapy (SMART) study, HIV-positive
current smokers had a two-fold risk of major cardiovas-
cular events as compared to non-smokers [3].
Respiratory complications of smoking include chronic
obstructive pulmonary disease (COPD) and respiratory
infections, such as bacterial pneumonia and pulmonary
tuberculosis (TB), and HIV infection may increase sus-
ceptibility to both of these [7,8].
Cigarette smoking is a major trigger for COPD in the
general population as well as in the HIV population,
and studies of HIV-positive patients have identified a
clear association between bacterial pneumonia and
smoking, with an over two-fold risk of bacterial pneu-
monia in HIV-positive current smokers as compared to
non-smokers [3].
In a research article published in BMC Medicine, Preeti
De and colleagues conducted a systematic review and
meta-analysis of cohort and case-control studies to assess
whether smoking cessation reduces the incidence of both
bacterial pneumonia and Pneumocystis pneumonia in
HIV-positive patients. The authors provide evidence that
HIV-positive current smokers are at increased risk for
bacterial pneumonia than former smokers. Moreover,
there is no evidence that HIV-positive former smokers
were at higher risk than never smokers, indicating that
smoking cessation reduces this risk. Thus, smoking ces-
sation programs should be systematically integrated into
HIV care.
However, further studies are needed to investigate
how long the risk of current smoking remains elevated
after stopping before the benefits of cessation become
manifest.
There is increasing evidence that smoking may also
have a major direct impact on pulmonary vasculature
and studies suggested that tobacco smoke causes a
pulmonary vascular remodelling that resembles that
occurring in patients with pulmonary hypertension, a
rare but severe manifestation in the course of HIV dis-
ease, leading to right ventricular failure and, ultimately,
death [9].
Smoking has also been demonstrated to be a signifi-
cant risk factor for TB. Recent meta-analyses indicated
that in the general population smokers are almost twice
as likely to be infected with TB (relative risk (RR)
around 1.5 for latent TB infection) and to progress to
active disease (RR around 2.0 for TB disease) [10-12].
The risk of developing TB is over 20 times greater in
HIV-positive patients than among those who do not
have HIV infection. If smoking increases the impact of
TB in HIV-negative patients, its effect in HIV-positive
patients may be significantly greater, with a deleterious
synergistic interaction between smoking, HIV and TB
[8].
HIV-positive patients who smoke have an increased
risk of a variety of opportunistic infections, including
oral and esophageal candidiasis [3,13]. Some studies
have also identified smoking as a risk factor for Pneumo-
cystis pneumonia [14], even though this association has
not been evidenced in the study by De et al.
A number of malignancies have also been associated
with HIV infection. For example, HIV-positive patients
are at increased risk for many cancers associated with
human papillomavirus, including cancer of the cervix,
anus, vulva, vagina, penis, oral cavity and pharynx [15].
However, previous findings of an association between
cigarette smoking and abnormal anal cytological
abnormalities among both HIV-positive women and
men, have not been more recently confirmed [16].
Lung cancer is the most important cause of non-
AIDS-defining malignancy in HIV-positive patients.
Although a number of studies have demonstrated that
HIV infection is associated with a significantly increased
risk for developing lung cancer, independently of smok-
ing status [17], smoking may additionally increase lung
cancer risk. For HIV-positive patients in the SMART
study, the adjusted hazard ratio for lung cancer for cur-
rent versus never smokers was 9.4 [3].
HIV-positive patients may be at greater risk for meta-
bolic bone disease, including osteopenia and osteoporo-
sis [18]. Smoking has been associated with an increased
risk of loss of bone density, and is an independent risk
factor for fractures among HIV-positive patients [19].
Smoking and survival in HIV-positive patients
HIV-positive patients who smoke have significantly
increased mortality compared to those who have never
smoked [3,4]. In a US veterans study, the mortality rate
per 100 person-years was 1.76 for HIV-negative never
smokers, 2.45 for HIV-positive never smokers and 5.48
Table 1 Clinical conditions influenced by smoking in HIV-
positive patients








Opportunistic infections -Oral candidiasis
-Oesophageal candidiasis
-Pneumocystis pneumonia
Bone disease and fractures
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for HIV-positive current smokers, suggesting that both
HIV infection and smoking contribute to increased mor-
tality compared to never smokers [4].
In a recently published article from the Danish HIV
Cohort study, it has been observed that the excess mor-
tality of smokers is tripled and the population-attributa-
ble risk of death associated with smoking is doubled
among HIV-positive patients compared to the back-
ground population [20]. These data indicate that smok-
ing confers different mortality risk in HIV-positive than
in HIV-negative patients, and lifestyle-related factors
may pose a greater hazard to long-term survival of HIV-
positive patients than those related to the HIV infection
itself.
Moreover, mortality was lower among previous com-
pared to current smokers and this emphasizes the
importance of counselling HIV-positive patients on
smoking cessation, as smoking may impact their life
expectancy considerably more than HIV infection per se
[20].
Smoking cessation as a prevention tool
Although further studies are needed to elucidate
whether smoking has an additive or synergistic effect on
cardiovascular, pulmonary and neoplastic diseases in
HIV-positive patients, without doubt smoking is the pre-
ventable factor that accounts for the highest number of
life-years lost in the general population and, particularly,
in the HIV population.
However, although large clinical evidence exists to
support the use of a variety of smoking cessation inter-
ventions in the general population, there are no clinical
practice guidelines to guide the provision of smoking
cessation treatment in HIV-positive patients.
The high prevalence of smoking among the HIV
population, the many health risks that can result from
it, and the proven efficacy of cessation interventions in
HIV-positive patients should encourage clinicians to
make smoking cessation for their patients a high
priority.
HIV-positive patients should be screened for smoking,
and current smokers should be enrolled in smoking ces-
sation programs as a part of care in HIV-positive
patients.
HIV-positive smokers need to be informed about the
impact of smoking on HIV disease and its treatment. In
a setting where HIV care is well organized and ART is
available free of charge, HIV-positive smokers should be
aware that they lose more life-years to smoking than to
HIV infection [20].
Conclusions
The bulk of evidence supports the need for smoking
cessation in HIV-positive patients. Life quality and
expectancy could improve as a consequence of this
behavioral change.
In the article by De et al., it has been shown that
smoking cessation is causally associated with a reduced
risk of bacterial pneumonia in HIV-positive patients.
Therefore, all the efforts of clinicians and other HIV-
care providers should be addressed to prevent all the
co-factors that increase the risk for AIDS- and non-
AIDS-related diseases.
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